Sales of Roche’s Rituxan Have Started to Decline as Biosimilars Thereof are Marketed

Sales of Roche’s Rituxan Have Started to Decline as Biosimilars Thereof are Marketed

Author: 1℃

Celltrion and Teva Pharmaceutical released big news on October 11, 2018 that the Rituxan? (rituximab) biosimilar. After the marketing, CT-P10 will become the first Rituxan? (rituximab) biosimilar approved for marketing in the U.S.

Read the full article:

Sales of Roche’s Rituxan Have Started to Decline as Biosimilars Thereof are Marketed

-----------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: [email protected].

要查看或添加评论,请登录

Julia Zhang的更多文章

社区洞察

其他会员也浏览了